Palatin updates on PL9643 dry eye Phase 3 lead-in data and PL8177 UC data

PALATIN TECHNOLOGIES INC

PL9643 lead-in data from MELODY-1 Phase 3 shows excellent ocular tolerability and broad efficacy on dry eye signs/symptoms.
PL8177 preclinical data in rat UC models reduces colonic damage; oral formulation delivers to colon without systemic absorption.
Phase 2 study PL8177-205 for UC enrolling; interim and topline data expected in 2H2023.
KOL webinar replay with Dr. Stouch, Ousler, Raizman available on Palatin website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.